Carregant...
The need for additional genetic markers for MDS stratification: what does the future hold for prognostication?
Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematopoietic disorders. Metaphase cytogenetics (MC) has been the gold standard for genetic testing in MDS, but it can detect clonal cytogenetic abnormalities in only 50% of cases. New karyotyping tests include fluorescence i...
Guardat en:
| Publicat a: | Expert Rev Hematol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4535709/ https://ncbi.nlm.nih.gov/pubmed/23373781 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/ehm.12.67 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|